#LCSM Chat 2019/01/06–Immunotherapy: What Patients Need To Know

It’s a new year, and #LCSM Chat is transitioning to monthly chats.  Our first chat is a collaborative chat across all cancer hashtag communities titled “Immunotherapy: What Patients Need to Know.” The discussion will cover all types of immunotherapy currently approved for treatment of any cancer. Chat moderator Janet Freeman-Daily (@JFreemanDaily) will be joined by special guest Lisa Rezende (@LisaRezende1), a biology educator (Assistant Professor of Practice) on the Molecular and Cellular Biology faculty at the University of Arizona.  Lisa is also a long-term volunteer cancer advocate with FORCE (Facing Our Risk of… Read More

#LCSM Chat Topic 10/04/2018: Highlights from #WCLC2018

After a summer hiatus, #LCSM Chat is returning to Twitter!  Our first chat of the fall will be on Thursday, October 04, at 5pm Pacific Time (8 pm Eastern).  We will be reviewing key presentations from the IASLC 19th World Conference on Lung Cancer (#WCLC2018) held September 23-26 in Toronto, Canada.  Our special guests for this chat will be the Communications Team from the International Association for the Study of Lung Cancer (IASLC), the organizers of WCLC, and our moderator will be Janet Freeman-Daily (@JFreemanDaily). WCLC abstracts may be oral presentations (20… Read More

#LCSM Chat topic 6/14/2018: Immunotherapy–the ultimate personalized therapy

Immunotherapy has revolutionized cancer care, particularly for lung cancer patients.  On Thursday, June 14, 2018, at 8 PM Eastern time (5 PM Pacific), #LCSM Chat moderator Brendon Stiles (@BrendonStilesMD) will lead our discussion on “Immunotherapy–the ultimate personalized therapy.” Over the last few years, several “checkpoint inhibitors” have been approved by the FDA for lung cancer patients.  Because these drugs essentially unleash brakes on T cells which allow each patient’s own immune system to kill their cancer cells, these drugs could be considered the ultimate personalized therapy for cancer.  In fact, these drugs… Read More